Upstream Bio Stock Price Prediction
| UPB Stock | 27.15 0.17 0.62% |
Momentum 62
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.79) | EPS Estimate Current Year (2.70) | EPS Estimate Next Year (3.21) | Wall Street Target Price 49.75 | EPS Estimate Current Quarter (0.78) |
Using Upstream Bio hype-based prediction, you can estimate the value of Upstream Bio from the perspective of Upstream Bio response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Upstream Bio using Upstream Bio's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Upstream using crowd psychology based on the activity and movement of Upstream Bio's stock price.
Upstream Bio Implied Volatility | 2.25 |
Upstream Bio's implied volatility exposes the market's sentiment of Upstream Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Upstream Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Upstream Bio stock will not fluctuate a lot when Upstream Bio's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Upstream Bio to buy its stock at a price that has no basis in reality. In that case, they are not buying Upstream because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Upstream Bio after-hype prediction price | USD 26.91 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Upstream contract
Based on the Rule 16, the options market is currently suggesting that Upstream Bio will have an average daily up or down price movement of about 0.14% per day over the life of the 2026-03-20 option contract. With Upstream Bio trading at USD 27.15, that is roughly USD 0.0382 . If you think that the market is fully incorporating Upstream Bio's daily price movement you should consider acquiring Upstream Bio options at the current volatility level of 2.25%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Upstream Bio Basic Forecasting Models to cross-verify your projections. Upstream Bio After-Hype Price Prediction Density Analysis
As far as predicting the price of Upstream Bio at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Upstream Bio or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Upstream Bio, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Upstream Bio Estimiated After-Hype Price Volatility
In the context of predicting Upstream Bio's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Upstream Bio's historical news coverage. Upstream Bio's after-hype downside and upside margins for the prediction period are 22.64 and 31.18, respectively. We have considered Upstream Bio's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Upstream Bio is not too volatile at this time. Analysis and calculation of next after-hype price of Upstream Bio is based on 3 months time horizon.
Upstream Bio Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Upstream Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Upstream Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Upstream Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.66 | 4.27 | 0.24 | 0.64 | 7 Events / Month | 8 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
27.15 | 26.91 | 0.88 |
|
Upstream Bio Hype Timeline
On the 2nd of January Upstream Bio is traded for 27.15. The entity has historical hype elasticity of -0.24, and average elasticity to hype of competition of 0.64. Upstream is projected to decline in value after the next headline, with the price expected to drop to 26.91. The average volatility of media hype impact on the company price is over 100%. The price depreciation on the next news is expected to be -0.88%, whereas the daily expected return is at this time at 0.66%. The volatility of related hype on Upstream Bio is about 439.3%, with the expected price after the next announcement by competition of 27.79. About 15.0% of the company outstanding shares are owned by insiders. The book value of Upstream Bio was at this time reported as 7.01. The company recorded a loss per share of 6.4. Upstream Bio had not issued any dividends in recent years. Considering the 90-day investment horizon the next projected press release will be in about 7 days. Check out Upstream Bio Basic Forecasting Models to cross-verify your projections.Upstream Bio Related Hype Analysis
Having access to credible news sources related to Upstream Bio's direct competition is more important than ever and may enhance your ability to predict Upstream Bio's future price movements. Getting to know how Upstream Bio's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Upstream Bio may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ZBIO | Zenas BioPharma Common | 2.17 | 11 per month | 5.42 | 0.14 | 13.19 | (8.10) | 52.76 | |
| NTLA | Intellia Therapeutics | 0.83 | 9 per month | 0.00 | (0.08) | 11.23 | (8.86) | 61.94 | |
| WVE | Wave Life Sciences | (0.01) | 9 per month | 3.97 | 0.12 | 11.43 | (8.08) | 164.47 | |
| RLAY | Relay Therapeutics | 0.28 | 10 per month | 2.95 | 0.17 | 9.62 | (5.31) | 27.25 | |
| PHVS | Pharvaris BV | 0.67 | 8 per month | 3.47 | 0.05 | 7.01 | (5.72) | 27.49 | |
| SNDX | Syndax Pharmaceuticals | (0.34) | 9 per month | 2.31 | 0.12 | 8.88 | (4.98) | 18.09 | |
| NVAX | Novavax | (0.21) | 9 per month | 0.00 | (0.13) | 4.02 | (4.83) | 15.41 | |
| AMLX | Amylyx Pharmaceuticals | 0.41 | 6 per month | 0.00 | (0.09) | 7.34 | (5.24) | 17.17 | |
| TERN | Terns Pharmaceuticals | 2.57 | 11 per month | 2.55 | 0.27 | 13.30 | (5.80) | 76.18 | |
| SYRE | Spyre Therapeutics | 3.35 | 10 per month | 2.25 | 0.24 | 10.99 | (3.90) | 29.33 |
Upstream Bio Additional Predictive Modules
Most predictive techniques to examine Upstream price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Upstream using various technical indicators. When you analyze Upstream charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Upstream Bio Predictive Indicators
The successful prediction of Upstream Bio stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Upstream Bio, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Upstream Bio based on analysis of Upstream Bio hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Upstream Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Upstream Bio's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 17.96 | 44.63 | 40.16 | 42.17 | Net Debt To EBITDA | 0.64 | 4.17 | 3.75 | 3.94 |
Story Coverage note for Upstream Bio
The number of cover stories for Upstream Bio depends on current market conditions and Upstream Bio's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Upstream Bio is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Upstream Bio's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Upstream Bio Short Properties
Upstream Bio's future price predictability will typically decrease when Upstream Bio's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Upstream Bio often depends not only on the future outlook of the potential Upstream Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Upstream Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 51.3 M | |
| Cash And Short Term Investments | 470.5 M |
Complementary Tools for Upstream Stock analysis
When running Upstream Bio's price analysis, check to measure Upstream Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio is operating at the current time. Most of Upstream Bio's value examination focuses on studying past and present price action to predict the probability of Upstream Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio's price. Additionally, you may evaluate how the addition of Upstream Bio to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |